DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 186 filers reported holding DENALI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,914 | +34.2% | 626 | +92.0% | 0.00% | – |
| Q2 2023 | $9,620 | +88.9% | 326 | +47.5% | 0.00% | – |
| Q1 2023 | $5,092 | +92.7% | 221 | +132.6% | 0.00% | – |
| Q4 2022 | $2,642 | +164.2% | 95 | +137.5% | 0.00% | – |
| Q3 2022 | $1,000 | – | 40 | +700.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 5 | -90.6% | 0.00% | – |
| Q1 2022 | $2,000 | -50.0% | 53 | -20.9% | 0.00% | – |
| Q1 2021 | $4,000 | +300.0% | 67 | +570.0% | 0.00% | – |
| Q4 2020 | $1,000 | – | 10 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |